AstraZeneca and Memorial Sloan Kettering Partner with IgniteData for Innovative Phase 3 Trial

AstraZeneca and Memorial Sloan Kettering Cancer Center (MSK) have announced a collaboration with digital health technology company IgniteData to implement an automated data capture tool in a phase 3 clinical trial. This partnership marks a significant step forward in streamlining clinical trial data management and accelerating research processes.

Automated Data Capture Tool Revolutionizes Trial Data Management

IgniteData's proprietary tool, Archer, will be utilized to automatically transfer data from electronic health records at hospitals directly to trial sponsors. This innovative approach eliminates the need for manual data entry, potentially reducing errors and significantly speeding up the data transfer process.

Joe Lengfellner, senior director of clinical research information technology at MSK, emphasized the importance of this development, stating, "The implementation of Archer in this AstraZeneca-sponsored phase 3 study demonstrates the growing industry-academia alignment on the future of trial data management. This convergence will accelerate trial execution and improve data quality across the clinical research ecosystem."

Expansion Following Successful Pilot Program

The implementation of Archer in this phase 3 trial comes after a successful pilot program. IgniteData plans to use insights gained from each deployment to refine the tool, with the ultimate goal of broader implementation across research sites worldwide.

This move aligns with a growing trend in the pharmaceutical industry to leverage advanced technologies for improved clinical trial efficiency. Other companies, such as Flatiron Health, are also developing similar automated data capture tools, indicating a shift towards more streamlined and technologically advanced clinical research processes.

Implications for Future Clinical Trials

The adoption of IgniteData's Archer tool by AstraZeneca and MSK could have far-reaching implications for the conduct of clinical trials. By automating data capture and transfer, researchers can potentially reduce the time and resources required for data management, allowing for faster trial completion and potentially accelerating the drug development process.

As the pharmaceutical industry continues to embrace digital health technologies, partnerships like this one between AstraZeneca, MSK, and IgniteData are likely to become increasingly common, paving the way for more efficient and accurate clinical research.